Transvenous leads are the most common source of complications associated with the use of implantable cardioverter-defibrillators (ICDs). A preliminary experience with an entirely subcutaneous ICD ...

Cardiac device therapy has significantly evolved since the introduction of the first implantable pacemaker and the subsequent ...

Please provide your email address to receive an email when new articles are posted on . A subcutaneous implantable cardioverter defibrillator was noninferior to a transvenous ICD regarding major ...

Last year the FDA approved Boston Scientific's subcutaneous ICD, the first ICD that can defibrillate the heart without using leads threaded to the heart through the blood vessels. Those leads are the ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous implantable cardioverter defibrillators can be extracted safely and feasibly. S-ICD extraction was ...

In a typical population of patients requiring implantable cardioverter-defibrillator (ICD) therapy without pacing, mostly for the primary prevention of sudden cardiac death, a subcutaneous ICD (S-ICD; ...

SAN FRANCISCO, CA—The subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific) prevents most of the major lead-related complications seen with a transvenous system, the ATLAS ...

Years ago, during training, I remember a colleague dissing an early model of an implantable cardioverter-defibrillator (ICD) because it was primitive. All it did was shock ventricular tachycardia (VT) ...

The FDA’s Circulatory System Devices panel voted 7-1 on Thursday that the benefits of the Cameron Health subcutaneous ICD system (S-ICD) outweigh the risks in appropriately selected patients. The ...

Stockholm, Sweden - Early testing of an implantable cardioverter-defibrillator (ICD) featuring a totally subcutaneous lead system suggests the device can terminate ventricular tachyarrhythmias using ...